Objective: Determine uptake of prostate-specific antigen (PSA) testing in Medicare beneficiaries according to previous receipt of PSA testing.
Introduction
Prostate cancer is among the most frequently diagnosed cancers in the United States, both overall and in the Medicare-eligible population (aged 65 years or older) [1] . Despite the high incidence and mortality associated with prostate cancer [1] , the merits of prostate-specific antigen (PSA) screening in the general population are controversial. In 2008, the US Preventive Services Task Force (USPSTF) initially determined that there was insufficient evidence to recommend or not recommend routine prostate cancer screening with either PSA testing or digital rectal examination in men younger than 75 years [2] . In contrast, it concluded that the potential harms of screening would outweigh the benefits in men aged 75 years or older. In May 2012, the revised USPSTF guidelines recommended that prostate cancer screening no longer be performed by either method in men who are of average risk of having prostate cancer [3] . Other guidelines, including those of the American Cancer Society [4] , the American
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Urological Association [5] , and most recently, the National Comprehensive Cancer Network [6] recommended that men who are aged 50-74 years, 55-69 years, and 45-75 years respectively and have at least a 10-year life expectancy should have an opportunity to make an informed decision with their health care provider about whether to be screened for prostate cancer. In addition, the American Urological Association guidelines recommend every other year testing among men who elect to have PSA screening [5] .
Previous studies have used administrative data, including Medicare claims and Veterans Administration files, to examine the use of PSA testing according to age and publication of practice guidelines and clinical trial data [7] [8] [9] [10] [11] [12] . Studies have documented variability in the use of screening according to geographic region [12] and physician characteristics [11] , as well as a modest decline in screening following the publication of the 2008 [8, 11, 13] and 2012 [14] [15] [16] [17] USPSTF guidelines [2, 3] and screening trial publications [18, 19] . Three recently published studies used data from the National Health Interview Survey [20] [21] [22] and reported declines in PSA testing use following publication of the USPSTF guidelines.
However, despite the consensus that if PSA testing is offered, it should be performed on a regular (i.e., annual or biannual) basis, all studies have used a cross-sectional approach to measure screening. In these studies, PSA testing was considered as a one-time event and patients were not stratified according to previous use of screening or whether they were up to date with screening.
We therefore performed a population-based analysis with Medicare claims data to determine the use of PSA testing according to receipt of previous screening. In addition to measures of previous PSA testing, our analyses also considered factors such as sociodemographics, comorbidity, and physician supply. We hypothesized that the frequency of screening did not change among men who were already undergoing testing but declined in men who were previously not screened.
Methods
Data sources
The study cohort included claims from a 5% random sample To limit the analysis to PSA testing performed for probable screening indications as opposed to surveillance or symptom evaluation, we used a previously developed and validated algorithm to increase the specificity of PSA testing [6] . In addition to a prostate cancer diagnosis, this algorithm also excluded men with a history of prostatectomy, androgen deprivation therapy, or elevated PSA level, and also urinary symptoms within 3 months before the PSA test claim. ity index that included both outpatient and inpatient diagnosis codes was included for the 12-month to 1-month period before the PSA test date or the end of the follow-up period [23] . As previously defined, to exclude "rule out" diagnoses, a comorbid condition had to appear more than once in outpatient files.
Measures
The Beneficiary Summary File contained fields for state buyin and dual eligibility, which indicate lower socioeconomic status and/or with heightened vulnerability. The geographic region of residence was divided into Northeast, Midwest, South, and West.
During each calendar month, we considered the proportion of eligible men who received one or more PSA tests, divided by the number of men who were otherwise eligible for screening and who had not received a PSA test during the previous 24 months. Men were included in the numerator only if they actually received a PSA test during that month, and the denominator changed from month to month as new men became due for testing. PSA tests were identified through relevant procedure codes (CPT-4 84153, G0103).
To account for delays in obtaining screening, a 90-day extension from the beneficiary's due date for repeated screening was used to satisfy the criterion for screening. This approach was previously used in a study of the impact of health care reform on receipt of mammography and colonoscopy [24] .
Beneficiaries were censored at the month of death or disenrollment from fee-for-service Medicare plans on the basis of the Beneficiary Summary File. We also censored individuals 
Analysis
We first summarized PSA testing frequency by calendar month according to whether the patient was due for screening during that month (i.e., no PSA test in the previous 24 months). Because of the 90-day window to account for being up to date with testing, a cutoff for the due date of September 30, 2012, was used, and patients with due dates after that were excluded for calculation of frequencies for October through December 2012. The analyses were stratified according to whether the patient had no evidence of PSA testing during the previous 2-year period, or whether the patient had undergone testing during the previous 2 years and was due for repeated screening.
Univariate analysis was used to determine the association of calendar year with the use of PSA testing. Because individual patients were eligible for screening in more than 1 year, generalized estimating equation (GEE) logistic regression was used to account for within-patient correlation. In addition, as individual providers tend to have unique practice patterns with regard to PSA testing, we included physician clustering in the GEE regression models. We then used multivariate GEE models to determine the independent association of demographic, The characteristics of men with and without PSA testing are shown in Table 1 . The age distribution of the group with PSA testing was somewhat in favor of older age compared with the group without PSA testing, whereas the racial and ethnic distribution was similar between the two groups. The PSA group had a higher proportion of men with at least one comorbid condition. Men with PSA testing were 112 ORIGINAL RESEARCH The results of the multivariate GEE analyses for men with previous PSA testing are shown in Table 2 . PSA testing was less common in African Americans and men in the northeastern United States. There was minimal or no association of median income or density of primary care physicians, but screening tended to be more frequent in regions with higher median educational levels. However, PSA testing use was highest in regions with a greater density of urologists.
There was no substantive association of calendar year through 2011 with PSA testing use, but use did decline in 2012.
In contrast, the multivariate results of PSA testing among men without previous screening differed across many parameters (Table 3) . In this group, there was a pronounced decline with older ages, but an increase in PSA testing use with higher levels of comorbidity. African Americans were less likely but members of other racial groups were more likely to be tested.
The highest use of testing was found in the southern United
States, and PSA testing use tended to be highest in regions with higher median income and educational level. In contrast to men with previous screening, there was no consistent association with urologist density. Also, in contrast to the previously screened men, the frequency of PSA testing declined over time in men without recent screening, especially for 2012.
Discussion
Although prostate carcinoma is commonly diagnosed and is a leading cause of cancer-related death among men, the benefits and harms of PSA screening for this cancer in the general [3] [4] [5] [6] . Our study, which used a longitudinal design as opposed to the cross-sectional design from previous reports, found that testing patterns differed significantly depending on whether a patient had received PSA testing in the past.
Whereas the rates of PSA testing declined over time among previously unscreened men, screening frequency remained more constant among men with evidence of prior PSA testing.
In addition, although guidelines generally do not recommend screening in men aged 70-75 years or older [3] [4] [5] [6] , there was much less of a drop off in testing with age among men with previous PSA screening. The findings suggest that once a man is enrolled in a screening program, there is lower impact of changes in external practice guidelines.
Our study also found that for men without previous screening, an increase in PSA testing was associated with increased comorbidity, and a decrease was associated with advancing age. Although the comorbidity findings appear counterintuitive [25] , it may reflect more frequent contact with health care providers and hence a greater opportunity to order PSA testing. In addition, previous studies have documented aggressive treatment of low-risk prostate cancer among men with significant comorbidity [26] , suggesting that in contrast to
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Prior studies used administrative data from Medicare beneficiaries and the Department of Veterans Affairs as well as population-based surveys to examine the use of PSA testing according to patient characteristics, physician factors, geographic region, and changes in practice guidelines [7] [8] [9] [10] [11] [12] . Using a cross-sectional approach, these studies found PSA rates of up to 40%-50% during a defined time period, with only a modest decline with advancing age and comorbidity. There was also significant variability in the rate of PSA testing among primary care providers [11] , and it was more common in regions with greater total expenditures and end-of-life care [12] . Following publication of the 2008 USPSTF guidelines recommending routine screening not be performed in men older than 75 years, studies reported a modest decline in screening rates [8, 11, 13] . In addition, publication of clinical trial data was also associated with a 116 ORIGINAL RESEARCH small decrease in the use of screening [9] . Previous studies from single institutions also examined the potential impact of the 2012 USPSTF guidelines on screening. These studies documented a decline in the overall rate of PSA testing among primary care providers [16] and in prostate biopsies [15] . Three recently published articles used the National Health Interview Survey to examine PSA testing receipt before and after the publication of the 2012 USPSTF guidelines. One study found that although there was a significant decline in testing in men older than 50 years, there continued to be a high frequency of screening in men older than 75 years and/or with significant comorbidity [20] . Another study found that screening frequency increased from 2005 to 2008 but declined from 2010 to 2013, which correlated with a decrease in early-stage cancer incidence [21] . A third study found that the decrease in PSA testing from 2010 to 2013 was limited only to men younger than 75 years [22] .
In contrast, an analysis of the 2012 Behavioral Risk Factor Surveillance System data reported only a minimal decline in PSA testing receipt, with an estimate of 37.1% receiving PSA testing among men aged 50 years or older [16] . Because of differences in study design (cross-sectional vs. longitudinal) and use of monthly as opposed to yearly rates, the proportion of men with screening cannot be directly compared with our findings. However, the temporal trends that were observed were evident in most studies, including our own.
We recognize several important limitations with the use of Medicare claims data to measure PSA testing. First, the data were collected for billing purposes and not research, and thus lacked any clinical detail. For screening procedures, this includes the inability to differentiate screening versus surveillance or diagnostic indications, although we used a previously validated algorithm with a higher specificity for screening indications [6] and excluded men with a previous prostate cancer diagnosis. In addition, the accuracy of claims data for measuring PSA testing use is thought to be high [27] .
Our study design also could not measure patient and physician preferences regarding screening, both of which were likely associated with screening receipt. However, the results were clustered by provider, which accounts in part for physician practice patterns. Because of incomplete claims data, the study did not include men who were enrolled in Medicare Advantage Plans or those not enrolled in Medicare Part B, and it was not known if the trends of PSA testing use in these groups would be similar. The study was also limited to an older patient population, and thus the impact of guidelines and other factors in younger, privately insured individuals could not be measured. Moreover, despite the lack of USPSTF recommendations, PSA testing has remained a covered benefit under Medicare without any out-of-pocket expenses. Analyses in younger patient groups have found mixed results with regard to changes in PSA testing uptake after 2012 [20] [21] [22] . Finally, because patient-level socioeconomic status was not available in claims data, we used small area measures, a commonly used approach in studies of Medicare data.
In summary, we found that receipt of PSA testing is highly dependent on whether an individual was tested in the recent on whether an individual was tested in the recent past.
